Intralesional epidermal growth factor therapy for diabetic foot ulcers: an evaluation of 15 cases

Basit Öğe Kaydı
dc.contributor.authorIsikgoz Tasbakan, Meltem
dc.contributor.authorYildirim Simsir, Ilgin
dc.contributor.authorMermer, Sinan
dc.contributor.authorUysal, Serhat
dc.contributor.authorOzturk, Murat
dc.contributor.authorCetinkalp, Sevki
dc.date.accessioned2019-10-27T11:19:40Z
dc.date.available2019-10-27T11:19:40Z
dc.date.issued2017
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground/aim: Intralesional recombinant epidermal growth factor (EGF) is a new treatment approach for diabetic foot ulcer, approved in 2006. EGF therapy is given as an adjunct to the standard treatment regimen of antibiotics, surgery, and hyperbaric oxygen. EGF accelerates the healing of diabetic foot ulcers and reduces healing time. This single-center study was conducted to evaluate the outcomes of intralesional EGF therapy in patients with diabetic foot ulcers. Materials and methods: We present the data of the follow-up patients treated in our clinics. Fifteen patients with diabetic foot ulcers or infections, who had been followed up and treated in our clinics, were included in this retrospective study. All patients were administered intralesional injections of 75 mu g of EGF after treatment for infection on their diabetic foot ulcers, three times a week on alternate days. The patients were monitored with respect to treatment response and side effects of EGF. Results: Thirteen patients (86.7%) developed new granulation tissue, 10 patients (66.7%) had complete wound closure, and three patients (20%) showed partial wound closure. No serious side effects requiring discontinuation of EGF therapy were observed. A total of twenty-one bacterial agents were isolated in thirteen patients, and no bacterial growth was observed in the tissue cultures of two patients. Pseudomonas aeruginosa was the most common isolated infectious agent in the tissue cultures (n: 6, 28%). Conclusion: Intralesional injection of EGF on top of the standard treatment regimen appears to be a useful adjuvant therapy option in selected patients.en_US
dc.identifier.doi10.3906/sag-1703-153en_US
dc.identifier.endpage1504en_US
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue5en_US
dc.identifier.pmid29151322en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1500en_US
dc.identifier.urihttps://doi.org/10.3906/sag-1703-153
dc.identifier.urihttps://hdl.handle.net/11454/32811
dc.identifier.volume47en_US
dc.identifier.wosWOS:000414976900026en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherTubitak Scientific & Technical Research Council Turkeyen_US
dc.relation.ispartofTurkish Journal of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectDiabetic footen_US
dc.subjectintralesional epidermal growth factoren_US
dc.subjectwound healingen_US
dc.titleIntralesional epidermal growth factor therapy for diabetic foot ulcers: an evaluation of 15 casesen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu